Platinum Based Chemotherapy for Advanced Epithelial Ovarian Cancer (AEOC)

Abstract

Between January 1987 to December 1989, thirty-seven patients with advanced epithelial ovarian cancer were treated with various Platinum based chemotherapy according to their financial status. Regimen A consisted of cisplatin, doxorubicin and cyclophosphamide. Regimen B was cisplatin and melphalan. Overall response rates were 80% and 86% for regimen A and B, respectively and median duration of response were 21 and 15 months. The median survival was more than 35 months in both regimens. The proportions of “non responders” was similar in both treatment groups and the proportions in remission at various times following onset of treatment were also similar. When considering the cost effectiveness of treatment of 100 cases of advanced ovarian cancer, the reduction in costs of $ 77,160 would be obtained at the expense of 13 cases failing to survive past 35 months. (Thai J Obstet Gynaecol 1995;7:51-60.)